2024
The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature
Belzer A, Pach J, Valido K, Leventhal J. The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature. American Journal Of Clinical Dermatology 2024, 25: 435-445. PMID: 38366030, DOI: 10.1007/s40257-024-00847-2.Peer-Reviewed Original ResearchDermatologic adverse eventsAdverse eventsQuality of lifeManagement of dermatologic adverse eventsDiscontinuation of treatmentDermatology Life Quality IndexQuality of life of oncological patientsLife Quality IndexRadiation therapyCytotoxic chemotherapyDose reductionOral mucosaTargeted therapyOncological therapyProphylactic treatmentDrug classesEarly managementOncology patientsPatientsQuality-of-life concernsLife-prolonging treatmentTherapyPatient well-beingDeclining quality of lifeImpact patients
2023
Pseudocellulitis in oncology patients: A single institutional retrospective analysis investigating the clinical presentation, therapeutic response, and implications for cancer therapy
Pach J, Nelson C, Leventhal J. Pseudocellulitis in oncology patients: A single institutional retrospective analysis investigating the clinical presentation, therapeutic response, and implications for cancer therapy. JAAD International 2023, 12: 186-188. PMID: 37560470, PMCID: PMC10407291, DOI: 10.1016/j.jdin.2023.04.016.Peer-Reviewed Original ResearchImmune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment
Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. British Journal Of Dermatology 2023, 189: 339-341. PMID: 37140007, PMCID: PMC10947518, DOI: 10.1093/bjd/ljad149.Peer-Reviewed Original ResearchConceptsIL-13 expressionBullous pemphigoidImmune-related adverse eventsComplete disease clearancePromising new therapyNovel therapeutic approachesDisease clearanceAdverse eventsTumor immunityTherapeutic approachesNew therapiesConventional treatmentPemphigoidInterleukinTreatmentPatientsExpressionTherapyImmunityClearanceThe effect of baseline eczema or psoriasis on the morphology of cutaneous immune-related adverse events due to immune checkpoint inhibitor therapy
Belzer A, Mortlock R, Pach J, Cohen J, Leventhal J. The effect of baseline eczema or psoriasis on the morphology of cutaneous immune-related adverse events due to immune checkpoint inhibitor therapy. Journal Of The American Academy Of Dermatology 2023, 88: 1198-1200. PMID: 36634749, PMCID: PMC10121758, DOI: 10.1016/j.jaad.2023.01.002.Peer-Reviewed Original Research
2022
Dupilumab‐induced psoriasis in the setting of pembrolizumab therapy: an analysis of cytokine expression
Ahmad M, Murphy M, Damsky W, Leventhal J. Dupilumab‐induced psoriasis in the setting of pembrolizumab therapy: an analysis of cytokine expression. International Journal Of Dermatology 2022, 62: e424-e426. PMID: 36468831, DOI: 10.1111/ijd.16538.Peer-Reviewed Original ResearchPI3K Inhibitor Eruptions: an Overview of Diagnostic and Management Strategies for the Inpatient Dermatologist
Belzer A, Bhullar S, Leventhal J. PI3K Inhibitor Eruptions: an Overview of Diagnostic and Management Strategies for the Inpatient Dermatologist. Current Dermatology Reports 2022, 11: 158-167. DOI: 10.1007/s13671-022-00365-6.Peer-Reviewed Original ResearchDermatologic adverse eventsBody surface areaClinical trialsAdverse eventsCommon dermatologic adverse eventsMucositis/stomatitisFrequent adverse eventsAddition of prednisoneMajority of malignanciesPI3K inhibitorsMaculopapular rashProphylactic therapyPsoriasiform eruptionTopical corticosteroidsSun avoidanceSummaryThis reviewPI3KiK inhibitorsInpatient DermatologistTrialsCancer therapyRashTherapyDermatologistsOverview of diagnosticsSkin eruption involving bilateral breasts following radiation therapy for invasive ductal carcinoma of the left breast
Belzer A, McNiff JM, Leventhal JS. Skin eruption involving bilateral breasts following radiation therapy for invasive ductal carcinoma of the left breast. International Journal Of Women's Dermatology 2022, 8: e016. PMID: 35619675, PMCID: PMC9112382, DOI: 10.1097/jw9.0000000000000016.Peer-Reviewed Original Research
2021
Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer
Laird J, Leventhal J, Kanowitz J, Damast S. Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer. Practical Radiation Oncology 2021, 11: 448-452. PMID: 34157449, DOI: 10.1016/j.prro.2021.06.001.Peer-Reviewed Original ResearchErythema nodosum-like panniculitis associated with immune checkpoint inhibitor therapy: Two cases reporting a rare cutaneous adverse event
Pach J, Moody K, Ring N, Panse G, Zhang M, Deverapalli S, Leventhal J. Erythema nodosum-like panniculitis associated with immune checkpoint inhibitor therapy: Two cases reporting a rare cutaneous adverse event. JAAD Case Reports 2021, 13: 118-120. PMID: 34189226, PMCID: PMC8220292, DOI: 10.1016/j.jdcr.2021.05.002.Peer-Reviewed Original ResearchSubcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma
Pach J, Olamiju B, Weiss S, Damsky W, Leventhal J. Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma. JAMA Dermatology 2021, 157: 468-469. PMID: 33688919, DOI: 10.1001/jamadermatol.2021.0058.Peer-Reviewed Original Research
2020
Dermatologic toxicities associated with radiation therapy in women with breast cancer
Ramseier JY, Ferreira MN, Leventhal JS. Dermatologic toxicities associated with radiation therapy in women with breast cancer. International Journal Of Women's Dermatology 2020, 6: 349-356. PMID: 33898697, PMCID: PMC8060663, DOI: 10.1016/j.ijwd.2020.07.015.Peer-Reviewed Original ResearchBreast cancerRadiation therapyDermatologic toxicitiesEarly-stage breast cancerRadiation-induced morpheaAdjuvant radiation therapyBreast-conserving surgeryStage breast cancerStandard of careRadiation-induced fibrosisRadiation recallCutaneous toxicityRadiation dermatitisCutaneous sequelaeClinical presentationCutaneous malignanciesPatients' qualityTherapyCancerWomenToxicityMorpheaSequelaePatientsSurgeryNeoadjuvant anti–programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series
Ligtenberg KG, Hu JK, Damsky W, Olino K, Kluger H, Clune J, Cowper SE, Panse G, Leventhal J, Weiss SA. Neoadjuvant anti–programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series. JAAD Case Reports 2020, 6: 628-633. PMID: 32613057, PMCID: PMC7317689, DOI: 10.1016/j.jdcr.2020.05.010.Peer-Reviewed Case Reports and Technical NotesCutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist.
Tattersall IW, Leventhal JS. Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist. The Yale Journal Of Biology And Medicine 2020, 93: 123-132. PMID: 32226342, PMCID: PMC7087048.Peer-Reviewed Original ResearchConceptsCutaneous irAEsImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyImmune checkpoint inhibitionImmune checkpoint inhibitorsPotential adverse eventsPotential prognostic significanceNumber of cancersOnly carcinogenesisCheckpoint inhibitorsAdverse eventsCutaneous toxicityInhibitor therapyCheckpoint inhibitionPrognostic significanceCommon siteClinical characterizationPrimary dermatosesIrAEsTherapeutic promiseTreatment of diseasesTherapyCancerTreatmentDermatologists
2019
Dermatologic conditions in women receiving systemic cancer therapy
Ferreira MN, Ramseier JY, Leventhal JS. Dermatologic conditions in women receiving systemic cancer therapy. International Journal Of Women's Dermatology 2019, 5: 285-307. PMID: 31909148, PMCID: PMC6938835, DOI: 10.1016/j.ijwd.2019.10.003.Peer-Reviewed Original ResearchDermatologic conditionsDermatologic toxicitiesCancer therapyDermatologic adverse effectsCancer-related survivalImmune checkpoint inhibitorsNumber of patientsSystemic cancer therapyQuality of lifeCheckpoint inhibitorsEndocrine therapyOverall survivalMultidisciplinary careTimely diagnosisTreatment responseTraditional chemotherapyMucosal surfacesTherapyNovel therapeuticsMental healthAdverse effectsWomenToxic effectsCancerSevere instancesTopical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy
Atzmony L, Lim YH, Hamilton C, Leventhal JS, Wagner A, Paller AS, Choate KA. Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy. Journal Of The American Academy Of Dermatology 2019, 82: 123-131. PMID: 31449901, PMCID: PMC7039698, DOI: 10.1016/j.jaad.2019.08.043.Peer-Reviewed Original ResearchConceptsPorokeratosis lesionsPorokeratosis palmaris et plantaris disseminataPathogenesis-directed therapyTreatment of porokeratosisWeeks of therapyInitiation of therapyPathway gene mutationsDisseminated superficial actinic porokeratosisPathogenesis-based therapiesCase series designSuperficial actinic porokeratosisAdverse eventsTopical therapyTherapeutic optionsComplete clearanceLinear porokeratosisPatientsActinic porokeratosisTherapyPorokeratosisLesionsGene mutationsModerate improvementLovastatinToxic metabolites
2018
Pityriasis rubra pilaris–like erythroderma in the setting of pembrolizumab therapy responsive to acitretin
Coleman E, Panse G, Haldas J, Gettinger SN, Leventhal JS. Pityriasis rubra pilaris–like erythroderma in the setting of pembrolizumab therapy responsive to acitretin. JAAD Case Reports 2018, 4: 669-671. PMID: 30112450, PMCID: PMC6091308, DOI: 10.1016/j.jdcr.2018.06.022.Peer-Reviewed Original Research
2012
Is it time to re-evaluate the treatment of pemphigus?
Leventhal JS, Sanchez MR. Is it time to re-evaluate the treatment of pemphigus? Journal Of Drugs In Dermatology 2012, 11: 1200-6. PMID: 23134985.Peer-Reviewed Original ResearchConceptsIntravenous immunoglobulinCorticosteroid-related adverse effectsAdverse effectsTreatment of pemphigusCost of therapySerious adverse effectsManagement of pemphigusBest practice treatmentSystemic corticosteroidsClinical improvementMost patientsMucocutaneous diseaseStandard therapyBiologic agentsImmunosuppressive agentsPemphigus vulgarisBody of evidenceRecent trialsFatal infectionNovel therapiesTherapeutic strategiesPemphigusTherapyRemissionTreatment